(Q44245949)

1 December 2017

Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia (English)

1 reference

1 December 2017

1 reference

1 reference

Wayne Huey-Herng Sheu

2

object named as

Wayne Huey-Herng Sheu

1 reference

1 December 2017

I-Te Lee

1

1 reference

1 December 2017

Shih-Yi Lin

3

1 reference

1 December 2017

Wen-Jane Lee

4

1 reference

1 December 2017

Yuh-Min Song

5

1 reference

1 December 2017

Hui-Chen Liu

6

1 reference

1 December 2017

1 November 2002

1 reference

Journal of Diabetes and its Complications

1 December 2017

1 reference

1 December 2017

16

1 reference

1 December 2017

6

1 reference

1 December 2017

382-385

1 reference

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

Enhanced acute-phase response and oxidative stress in older adults with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

Increased serum concentration of von Willebrand factor in non-insulin dependent diabetic patients with and without diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

Body mass index, diabetes, and C-reactive protein among U.S. adults

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

Glycosylated hemoglobins and long-term blood glucose control in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

Role of novel markers of inflammation in patients with stable coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

Evaluating novel cardiovascular risk factors: can we better predict heart attacks?

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

Atherosclerosis — An Inflammatory Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900184-8

7 January 2021

10.1016/S1056-8727(02)00184-8

Identifiers

DOI

1 reference

1 December 2017

1 reference